

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
08 December 2022 (08.12.2022)



(10) International Publication Number  
**WO 2022/256290 A2**

(51) International Patent Classification:  
C12N 15/113 (2010.01) A61P 25/28 (2006.01)  
A61K 31/713 (2006.01)

(21) International Application Number:  
PCT/US2022/031519

(22) International Filing Date:  
31 May 2022 (31.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/196,791 04 June 2021 (04.06.2021) US

(71) Applicants: **ALNYLAM PHARMACEUTICALS, INC.**  
[US/US]; 675 West Kendall Street, Henri A. Termeer  
Square, Cambridge, MA 02142 (US). **REGENERON  
PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw  
Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors; and

(71) Applicants: **DANG, Lan, Thi Hoang** [US/US]; 675 West  
Kendall Street, Henri A. Termeer Square, Cambridge, MA  
02142 (US). **MCININCH, James, D.** [US/US]; 675 West  
Kendall Street, Henri A. Termeer Square, Cambridge, MA  
02142 (US). **NGUYEN, Tuyen, M.** [US/US]; 675 West  
Kendall Street, Henri A. Termeer Square, Cambridge, MA  
02142 (US). **DUBOSE, Brittany** [US/US]; c/o Regeneron  
Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tar-  
rytown, NY 10591 (US).

(72) Inventors: **FRENDEWEY, David**; c/o Regeneron Phar-  
maceuticals, Inc., 777 Old Saw Mill River Road, Tarry-  
town, NY 10591 (US). **SHARMA-KANNING, Aarti**; c/o  
Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River  
Road, Tarrytown, NY 10591 (US).

(74) Agent: **ZACHARAKIS, Maria, Laccotripe** et al.; Mc-  
Carter & English, LLP, 265 Franklin Street, Boston, MA  
02110 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished  
upon receipt of that report (Rule 48.2(g))

(54) Title: HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a human chromosome 9 open reading frame 72 (C9orf72) gene, as well as methods of inhibiting expression of a C9orf72 gene and methods of treating subjects having a C9orf72-associated disease or disorder, e.g., C9orf72 amyotrophic lateral sclerosis, frontotemporal dementia or Huntington-Like Syndrome Due To C9orf72 Expansions, using such dsRNAi agents and compositions.



WO 2022/256290 A2